FOXP1 and FOXO3a Are Prognostic Markers in Gallbladder Squamous Cell/Adenosquamous Carcinomas and Adenocarcinomas

医学 阶段(地层学) 腺鳞癌 内科学 免疫组织化学 转移 单变量分析 肿瘤科 腺癌 胆囊癌 病理 癌症 多元分析 生物 古生物学
作者
Jingjing Jiao,Ziru Liu,Xiong Li,Daiqiang Li,Qiong Zou,Yuan Yuan
出处
期刊:Applied Immunohistochemistry & Molecular Morphology [Lippincott Williams & Wilkins]
卷期号:30 (10): 703-712 被引量:2
标识
DOI:10.1097/pai.0000000000001061
摘要

The pathologic characteristics of squamous cell/adenosquamous carcinomas (SC/ASC) have not been well clarified. As a rare subtype of gallbladder cancer (GBC), no biological markers for diagnosis and prognosis are available. This research evaluated the expression of FOXP1 and FOXO3a in 69 SC/ASC, and 146 adenocarcinoma (AC) samples were analyzed via immunohistochemistry. SC/ASCs were associated with higher rates of lymph node metastasis, invasion, and patients older than 45 years comparing to ACs. FOXP1 and FOXO3a positivity rates were significantly lower in SC/ASC and AC samples from patients with large tumor size, a high TNM stage, lymph node metastasis, invasion, and no history of tumor resection (biopsy only). Positive FOXP1 expression levels were significantly decreased in cases of poorly differentiated AC. The univariate Kaplan-Meier analysis revealed that negative FOXP1 and FOXO3a expression, poor differentiation, large tumor size, high TNM stage, lymph node metastasis, invasion, and an inability to undergo curative resection were all closely associated with decreased overall survival in SC/ASC and AC patients. The multivariate cox regression analysis showed that negative FOXP1 and FOXO3a expression levels were independent predictors of poor prognosis in SC/ASC and AC patients. Our results indicate that negative FOXP1 and FOXO3a expression are closely associated with the pathogenesis, clinicopathologic properties, and prognosis of GBC patients. FOXP1 and FOXO3a may thus be biomarkers of GBC carcinogenesis, progression, and prognosis.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
李爱国应助科研通管家采纳,获得10
刚刚
慕青应助科研通管家采纳,获得10
1秒前
科研通AI2S应助科研通管家采纳,获得10
1秒前
今后应助科研通管家采纳,获得10
1秒前
科研通AI5应助科研通管家采纳,获得10
1秒前
Orange应助科研通管家采纳,获得10
1秒前
乐乐应助科研通管家采纳,获得10
1秒前
浮游应助科研通管家采纳,获得10
1秒前
浮游应助科研通管家采纳,获得10
1秒前
wanci应助科研通管家采纳,获得10
2秒前
核桃应助科研通管家采纳,获得10
2秒前
田様应助科研通管家采纳,获得10
2秒前
Owen应助科研通管家采纳,获得10
2秒前
所所应助科研通管家采纳,获得10
2秒前
nan完成签到,获得积分10
2秒前
核桃应助科研通管家采纳,获得10
2秒前
Lucas应助科研通管家采纳,获得10
2秒前
彭于晏应助科研通管家采纳,获得10
2秒前
FashionBoy应助科研通管家采纳,获得10
2秒前
斯文败类应助科研通管家采纳,获得10
2秒前
Orange应助科研通管家采纳,获得10
3秒前
香蕉觅云应助科研通管家采纳,获得10
3秒前
充电宝应助科研通管家采纳,获得10
3秒前
李爱国应助科研通管家采纳,获得10
3秒前
科研通AI5应助科研通管家采纳,获得30
3秒前
科研通AI6应助科研通管家采纳,获得30
3秒前
Akim应助科研通管家采纳,获得10
3秒前
3秒前
核桃应助科研通管家采纳,获得10
3秒前
浮游应助科研通管家采纳,获得10
3秒前
烟花应助科研通管家采纳,获得10
4秒前
科研通AI6应助科研通管家采纳,获得10
4秒前
4秒前
浮游应助科研通管家采纳,获得10
4秒前
4秒前
4秒前
4秒前
4秒前
4秒前
5秒前
高分求助中
Comprehensive Toxicology Fourth Edition 24000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Pipeline and riser loss of containment 2001 - 2020 (PARLOC 2020) 1000
World Nuclear Fuel Report: Global Scenarios for Demand and Supply Availability 2025-2040 800
Handbook of Social and Emotional Learning 800
Risankizumab Versus Ustekinumab For Patients with Moderate to Severe Crohn's Disease: Results from the Phase 3B SEQUENCE Study 600
Lloyd's Register of Shipping's Approach to the Control of Incidents of Brittle Fracture in Ship Structures 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5143116
求助须知:如何正确求助?哪些是违规求助? 4341139
关于积分的说明 13519750
捐赠科研通 4181415
什么是DOI,文献DOI怎么找? 2292915
邀请新用户注册赠送积分活动 1293554
关于科研通互助平台的介绍 1236153